*Refresh the page if the below document does not appear.
Vietnam calls India for help to maintain steady drug supplies
The Department of Pharmaceuticals in India received a communication from the high commission of Vietnam to allow them to participate in a Pharma event Scheduled for May 2023 with an agenda to promote trade and investment opportunities for both the countries.
CII declares Biosimilar sector to grow 30% by 2047
According to a report released on Friday by the CII (Confederation of Indian Industry), the biosimilars sector of biopharmaceutical industry is expected to rise over 30% and above by 2047 provided some Government reforms are made.
Ferring Pharma co invests more to expand gastro drug manufacturing in India
The Swiss company had already invested ₹500 crore in the last 5 years to setup an API (Active Pharmaceutical Ingredient) facility and an R&D Centre in India and now has decided to invest an additional ₹500 crores in expanding the gastro drug manufacturing over the next 3 years.
Bharat Biotech says PLI Schemes should focus on whole ecosystem of production in pharma
Bharat Biotech’s Executive Director Sai Prasad suggested that PLI (Production-linked incentive) schemes should equally focus on companies providing packaging materials and other services too. He also mentioned that domestic pharma sector should focus more on innovation.
Exemed pharmaceuticals receives approval to manufacture and market new drug
SEC (Subject expert Committee) under CDSCO gave a nod to the company for the production and sale of a FDC (Fixed Dose Combination) for Atorvastatin Calcium 80mg plus Bempedoic acid 180mg tablets indicated for the treatment of hypercholesterolemia.
Indian generic formulation manufacturers' decreasing Capex
An investment banking and consulting firm Candle Partners’ analyzed data shows the declining level of capex for Indian generic formulation pharma companies. Data shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block.
Edelweiss sends buy calls for Sun Pharma
The financial services company has a buy call
on Sun Pharmaceutical industries
(incorporated in the year 1993) with a target
price of ₹975, whereas the current market
price of Sun Pharmaceutical industries is
₹920.8